<DOC>
	<DOCNO>NCT00915993</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , MRI , may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This clinical trial study MRI predict response sunitinib malate patient stage IV kidney cancer .</brief_summary>
	<brief_title>MRI Predicting Response Sunitinib Malate Patients With Stage IV Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Correlate tumor vascular permeability dynamic contrast-enhanced MRI ( DCE MRI ) clinical outcome patient stage IV renal cell carcinoma treat sunitinib malate . - Correlate genetic histologic characteristic primary tumor vascular permeability DCE-MRI . Secondary - Correlate genetic histologic characteristic primary tumor clinical outcome patient treat sunitinib malate . - Collect tissue sample potential future exploratory analysis pharmacokinetic pharmacogenomic parameter . OUTLINE : Patients receive oral sunitinib malate daily day 1-28 . Treatment repeat every 42 day absence disease progression unacceptable toxicity . Patients undergo dynamic contrast-enhanced MRI baseline first 4 week sunitinib malate . Blood sample collect baseline periodically study pharmacokinetic analysis analysis angiogenic growth factor level . Tumor tissue sample collect baseline mutation analysis assessment angiogenesis histology IHC .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Stage IV disease Has undergone nephrectomy Archival tumor tissue sample available No history clinical evidence brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 WBC ≥ 3,000/mm^3 Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine ≤ 2.0 time upper limit normal ( ULN ) OR creatinine clearance ≥ 40 mL/min Total bilirubin ≤ 1.5 time ULN ( &lt; 3.0 time ULN patient Gilbert 's disease ) AST ALT ≤ 2.5 time ULN ( ≤ 5.0 time ULN patient liver metastasis ) INR ≤ 1.5 PTT normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexisting thyroid abnormality thyroidstimulating hormone maintain normal range medication No hypertension control medication ( i.e. , diastolic blood pressure ≥ 100 mm Hg despite optimal medical therapy ) No cardiac dysrhythmias ≥ grade 2 NCI CTCAE v3.0 No concurrent serious illness include , limited , follow : Ongoing active infection require parenteral antibiotic Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina ) NYHA class IIIV congestive heart failure Serious cardiac arrhythmia require medication Peripheral vascular disease ≥ grade 2 within past year Psychiatric illness and/or social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior antiangiogenesis therapy Prior radiotherapy symptomatic site metastatic disease allow At least 2 week since prior radiotherapy recover No concurrent investigational therapy No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) , rifampin , St. John 's wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>